Nano-X Imaging Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 37% year-over-year to $4.2 million, driven by Health IT and teleradiology growth, but a $40.7 million impairment led to a GAAP net loss of $55.5 million. Commercialization advanced with new installations, partnerships, and a CMS reimbursement code for AI solutions.
-
Revenue grew to $4.3M in Q1 2026, driven by teleradiology and Health IT, but cash burn and commercialization delays led to withdrawal of annual revenue guidance. Multiple new partnerships and restructuring efforts are underway, with a focus on operational milestones and cost control.
-
The presentation highlighted the company's FDA- and CE-cleared 3D imaging systems, innovative cold cathode technology, and expanding AI/software division. Commercialization is advancing in the U.S. and Europe, with flexible business models and strong operator margins.
Fiscal Year 2025
-
Q4 2025 saw expanded commercial agreements, a strategic acquisition, and a major manufacturing shift, driving a 23% revenue increase year-over-year. The company targets $35M revenue for 2026, with most growth expected in the second half as deployments ramp up.
-
Nanox.ARC X, a mobile 3D imaging system, and advanced AI tools received strong interest at RSNA and are now commercially deployed in the U.S. and EU. Financially, recent capital raises support expansion, with a focus on profitability and broadening clinical adoption.
-
Q3 2025 saw revenue growth to $3.4M and strong teleradiology margins, while the company closed the VasoHealthcare IT acquisition and expanded its European presence. Guidance for 2026 targets $35M+ revenue, with EBITDA break-even for AI in 2026 and company-wide in 2027.
-
Q2 2025 saw revenue growth to $3.0M and a GAAP net loss of $14.7M, with over 20 imaging systems actively scanning patients and a target of 100 installations by year-end. Expansion in the U.S. and Europe, new AI collaborations, and a scalable manufacturing agreement position the company for accelerated growth in the second half of 2025.
-
The event highlighted advances in 3D tomosynthesis imaging, AI-driven diagnostics, and cloud integration, with regulatory clearances and commercial deployments expanding globally. Innovative business models and partnerships support growth, aiming for break-even in AI by 2026 and significant hardware deployment by end of 2025.
-
A proprietary 3D digital imaging system with integrated AI and cloud solutions is being commercialized, following recent FDA and CE clearances. The business model includes both capex and pay-per-use options, with global deployments underway and strong financial backing as of March 2025.
-
Q1 2025 saw revenue growth to $2.8M and continued expansion of imaging and AI solutions, with over 60 ARC units in deployment and profitability in teleradiology. Break-even for AI is expected in 2026 and for ARC in 2027, with a major revenue inflection anticipated in H2 2025.
Fiscal Year 2024
-
Achieved key regulatory milestones with FDA and CE mark clearances, expanded U.S. and EU commercialization, and grew tele-radiology revenue and margins. AI solutions and imaging system deployments are gaining traction, supported by strong capital position and robust pipeline.
-
Q3 2024 saw expanded Nanox.ARC deployments, record teleradiology revenue, and strong AI traction, with regulatory milestones and international growth poised to drive future inflection. Cash reserves remain solid, and the company is scaling sales and support teams for broader adoption.
-
A novel 3D X-ray platform is advancing global commercialization with flexible business models, robust AI integration, and expanding clinical validation. Regulatory progress and a growing sales force support broader access and future product innovation.
-
Q2 2024 saw strong commercial and clinical progress, with expanded U.S. deployments, new FDA clearances, and improved financials. Revenue grew slightly, net loss narrowed, and the company is ramping up manufacturing and sales force to support further global expansion.